Stéphane Boissel

Stéphane Boissel

Directeur/Membre du Conseil chez ADOCIA
57 ans
Health Technology
Consumer Services
Commercial Services

Profil

Stéphane Boissel currently works at SparingVision SAS, as President, Chief Executive Officer & Director from 2023, Cottages Participations SAS, as Chairman, Adocia SA, as Independent Director from 2021, Transgene, Inc., as Director, Platine Pharma Services SAS, as Director, Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd., as Director, EG 427 SAS, as Director from 2021, and The French Society of Financial Analysts, as Member.
Mr. Boissel also formerly worked at Sangamo Therapeutics France SAS, as Chief Executive Officer, Genclis SA, as Chief Executive Officer from 2014 to 2015, ElsaLys Biotech SAS, as Non-Executive Chairman from 2013 to 2018, ERYTech Pharma SA, as Director from 2004 to 2009, Pharmaxon SAS, as Director, Sangamo Therapeutics, Inc., as Executive Vice President-Corporate Strategy from 2019 to 2020, Eurazeo SE, as Vice President from 1995 to 1998, Transgene SA, as Chief Financial Officer & Executive Vice President from 2010 to 2014, Innate Pharma SA, as Chief Financial Officer & Executive Vice President in 2010, Lazard Group LLC, as Vice President in 2002, France Biotech Association, as Member, PricewaterhouseCoopers France SARL, as Auditor in 1994, and Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., as Member-Supervisory Board.
Mr. Boissel received his graduate degree in 1993 from Université Paris Dauphine-PSL, undergraduate degree from the University of Lyon, and Masters Business Admin degree from The University of Chicago Booth School of Business.

Postes actifs de Stéphane Boissel

SociétésPosteDébut
ADOCIA Directeur/Membre du Conseil 21/05/2021
Directeur Général 21/10/2020
Président -
Corporate Officer/Principal -
Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd.
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -
Directeur/Membre du Conseil 01/03/2021

Anciens postes connus de Stéphane Boissel

SociétésPosteFin
SANGAMO THERAPEUTICS, INC. Directeur Financier/CFO 31/10/2019
░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░ ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░ ░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Stéphane Boissel

Formation de Stéphane Boissel

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

68

Relations au 1er degré

24

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées24

Health Technology

Finance

Health Technology

Health Technology

Finance

Consumer Services

Health Technology

Commercial Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Commercial Services

Consumer Services

Health Services

Commercial Services

Health Technology

Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd.

Health Technology

Miscellaneous

Health Technology

  1. Bourse
  2. Insiders
  3. Stéphane Boissel
DERNIÈRES HEURES | -40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT
🔇